SK14612003A3 - Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu - Google Patents
Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu Download PDFInfo
- Publication number
- SK14612003A3 SK14612003A3 SK1461-2003A SK14612003A SK14612003A3 SK 14612003 A3 SK14612003 A3 SK 14612003A3 SK 14612003 A SK14612003 A SK 14612003A SK 14612003 A3 SK14612003 A3 SK 14612003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- escitalopram
- treatment
- pharmaceutical composition
- diseases
- disorders
- Prior art date
Links
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title claims abstract description 54
- 229960004341 escitalopram Drugs 0.000 title claims abstract description 53
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 208000020401 Depressive disease Diseases 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 208000015238 neurotic disease Diseases 0.000 claims abstract description 7
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 4
- 208000035475 disorder Diseases 0.000 claims abstract description 4
- 208000032841 Bulimia Diseases 0.000 claims abstract description 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 3
- 208000030814 Eating disease Diseases 0.000 claims abstract description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 3
- 208000008589 Obesity Diseases 0.000 claims abstract description 3
- 208000022531 anorexia Diseases 0.000 claims abstract description 3
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 3
- 235000014632 disordered eating Nutrition 0.000 claims abstract description 3
- 235000020824 obesity Nutrition 0.000 claims abstract description 3
- 208000019899 phobic disease Diseases 0.000 claims abstract description 3
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 3
- 208000010877 cognitive disease Diseases 0.000 claims abstract 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 150000003891 oxalate salts Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010021567 Impulsive behaviour Diseases 0.000 claims description 2
- 230000037328 acute stress Effects 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 208000013403 hyperactivity Diseases 0.000 claims description 2
- 238000011221 initial treatment Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 208000018556 stomach disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 208000024714 major depressive disease Diseases 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 206010029333 Neurosis Diseases 0.000 abstract 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 abstract 1
- 208000026345 acute stress disease Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000024732 dysthymic disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 229960001653 citalopram Drugs 0.000 description 13
- 208000019901 Anxiety disease Diseases 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 230000036506 anxiety Effects 0.000 description 8
- 208000019906 panic disease Diseases 0.000 description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 206010033664 Panic attack Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 4
- 206010029897 Obsessive thoughts Diseases 0.000 description 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000033830 Hot Flashes Diseases 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- -1 7.5 mg or less Chemical compound 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200100684 | 2001-05-01 | ||
| PCT/DK2002/000281 WO2002087566A1 (en) | 2001-05-01 | 2002-05-01 | The use of enantiomeric pure escitalopram |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK14612003A3 true SK14612003A3 (sk) | 2004-04-06 |
Family
ID=8160464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1461-2003A SK14612003A3 (sk) | 2001-05-01 | 2002-05-01 | Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US20040198809A1 (enExample) |
| EP (1) | EP1385503A1 (enExample) |
| JP (1) | JP2004527551A (enExample) |
| KR (2) | KR20100012089A (enExample) |
| CN (1) | CN1509169A (enExample) |
| AR (1) | AR033308A1 (enExample) |
| AT (1) | AT10974U1 (enExample) |
| BG (1) | BG108379A (enExample) |
| BR (1) | BR0208283A (enExample) |
| CA (1) | CA2445843A1 (enExample) |
| CZ (1) | CZ20033267A3 (enExample) |
| EA (1) | EA200301195A1 (enExample) |
| HR (1) | HRP20030744A2 (enExample) |
| HU (1) | HUP0400054A3 (enExample) |
| IL (1) | IL158031A0 (enExample) |
| IS (1) | IS6954A (enExample) |
| ME (1) | MEP5908A (enExample) |
| MX (1) | MXPA03008777A (enExample) |
| NO (1) | NO20034538L (enExample) |
| PL (1) | PL367480A1 (enExample) |
| SK (1) | SK14612003A3 (enExample) |
| UA (1) | UA82828C2 (enExample) |
| WO (1) | WO2002087566A1 (enExample) |
| YU (1) | YU85303A (enExample) |
| ZA (1) | ZA200307102B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| YU85303A (sh) * | 2001-05-01 | 2006-05-25 | H. Lundbeck A/S | Upotreba enantiomerno čistog escitaloprama |
| ATE388947T1 (de) * | 2002-12-23 | 2008-03-15 | Lundbeck & Co As H | Escitalopramhydrobromid und ein verfahren zu dessen herstellung |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| EP2343073A3 (en) * | 2003-12-11 | 2011-10-12 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| US20050196453A1 (en) | 2004-03-05 | 2005-09-08 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
| CA2558198A1 (en) * | 2004-03-05 | 2005-09-15 | H. Lundbeck A/S | Crystalline composition containing escitalopram oxalate |
| TWI347942B (en) * | 2005-06-22 | 2011-09-01 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| CA2625835A1 (en) * | 2005-10-14 | 2007-05-10 | Forest Laboratories, Inc. | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
| EA200801080A1 (ru) * | 2005-10-14 | 2009-02-27 | Х. Лундбекк А/С | Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион |
| US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
| CN100353939C (zh) * | 2006-01-05 | 2007-12-12 | 昆明积大制药有限公司 | 含西酞普兰和环糊精的抗抑郁口服药用组合物 |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| US20070259952A1 (en) * | 2006-05-02 | 2007-11-08 | H. Lundbeck A/S | Uses of escitalopram |
| EP2086509A1 (en) * | 2006-10-20 | 2009-08-12 | Ratiopharm GmbH | Escitalopram and solid pharmaceutical composition comprising the same |
| US20100003313A1 (en) * | 2006-10-27 | 2010-01-07 | Hisamitsu Pharmaceutical Co.,Inc. | Adhesive skin patch |
| EP2017271A1 (en) | 2007-07-06 | 2009-01-21 | Aurobindo Pharma Limited | Process for the preparation of escitalopram |
| NO2185155T3 (enExample) * | 2007-08-03 | 2018-03-03 | ||
| SG185969A1 (en) * | 2008-01-31 | 2012-12-28 | Takeda Pharmaceutical | Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder |
| ITMI20080768A1 (it) * | 2008-04-24 | 2009-10-25 | Abiogen Pharma Spa | Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one |
| WO2010098230A1 (ja) * | 2009-02-27 | 2010-09-02 | 久光製薬株式会社 | 経皮投与製剤 |
| US20180071269A1 (en) | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
| WO2016180879A1 (en) * | 2015-05-13 | 2016-11-17 | A. Carlsson Research Ab | Treatment of debilitating fatigue |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1143703A (enExample) * | 1965-03-18 | |||
| US4079135A (en) * | 1973-12-13 | 1978-03-14 | Imperial Chemical Industries Limited | Morpholine derivatives as antidepressants |
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8607313D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
| US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| US5296507A (en) * | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
| US5708035A (en) * | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
| EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| US5627196A (en) * | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
| US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
| US5747494A (en) * | 1996-06-28 | 1998-05-05 | U C B S.A. | Pharmaceutical compositions for the treatment of depressive disorders |
| US5958429A (en) * | 1996-08-16 | 1999-09-28 | Eli Lilly And Company | Potentiation of serotonin response |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US5776969A (en) * | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
| US6069177A (en) * | 1997-07-08 | 2000-05-30 | The Hong Kong University Of Science And Technology | 3-Hydroxy-propanamine derived neuronal reuptake inhibitors |
| SE9703375D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| WO1998019512A2 (en) * | 1997-11-11 | 1998-05-14 | H. Lundbeck A/S | Method for the preparation of citalopram |
| EP1100501A4 (en) * | 1998-06-30 | 2002-12-04 | Lilly Co Eli | PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN |
| US6150376A (en) * | 1998-08-05 | 2000-11-21 | Georgetown University | Bi- and tri-cyclic aza compounds and their uses |
| HU228576B1 (en) * | 1998-10-20 | 2013-04-29 | Lundbeck & Co As H | Method for the preparation of citalopram |
| PT1173431E (pt) * | 1999-04-14 | 2003-09-30 | Lundbeck & Co As H | Metodo de preparacao do citalopram |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| US6333357B1 (en) * | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
| WO2001080845A2 (en) * | 2000-04-24 | 2001-11-01 | Aryx Therapeutics | (2-aminoethyl) oxime derivatives for the treatment of depression |
| YU85303A (sh) * | 2001-05-01 | 2006-05-25 | H. Lundbeck A/S | Upotreba enantiomerno čistog escitaloprama |
-
2002
- 2002-05-01 YU YU85303A patent/YU85303A/sh unknown
- 2002-05-01 MX MXPA03008777A patent/MXPA03008777A/es unknown
- 2002-05-01 EA EA200301195A patent/EA200301195A1/ru unknown
- 2002-05-01 CA CA002445843A patent/CA2445843A1/en not_active Abandoned
- 2002-05-01 SK SK1461-2003A patent/SK14612003A3/sk not_active Application Discontinuation
- 2002-05-01 HR HR20030744A patent/HRP20030744A2/xx not_active Application Discontinuation
- 2002-05-01 BR BR0208283-7A patent/BR0208283A/pt not_active IP Right Cessation
- 2002-05-01 KR KR1020097027003A patent/KR20100012089A/ko not_active Ceased
- 2002-05-01 JP JP2002584912A patent/JP2004527551A/ja active Pending
- 2002-05-01 KR KR10-2003-7014286A patent/KR20040030609A/ko not_active Ceased
- 2002-05-01 WO PCT/DK2002/000281 patent/WO2002087566A1/en not_active Ceased
- 2002-05-01 EP EP02724141A patent/EP1385503A1/en not_active Withdrawn
- 2002-05-01 IL IL15803102A patent/IL158031A0/xx unknown
- 2002-05-01 CN CNA028092309A patent/CN1509169A/zh active Pending
- 2002-05-01 UA UA2003098415A patent/UA82828C2/xx unknown
- 2002-05-01 ME MEP-59/08A patent/MEP5908A/xx unknown
- 2002-05-01 PL PL02367480A patent/PL367480A1/xx not_active Application Discontinuation
- 2002-05-01 CZ CZ20033267A patent/CZ20033267A3/cs unknown
- 2002-05-01 US US10/468,685 patent/US20040198809A1/en not_active Abandoned
- 2002-05-01 HU HU0400054A patent/HUP0400054A3/hu unknown
- 2002-05-02 AR ARP020101612A patent/AR033308A1/es unknown
-
2003
- 2003-08-20 US US10/644,579 patent/US20040192765A1/en not_active Abandoned
- 2003-08-20 US US10/644,588 patent/US20040192766A1/en not_active Abandoned
- 2003-08-20 US US10/644,576 patent/US20040192764A1/en not_active Abandoned
- 2003-08-20 US US10/644,577 patent/US20040198810A1/en not_active Abandoned
- 2003-08-20 US US10/644,587 patent/US20040198811A1/en not_active Abandoned
- 2003-09-11 ZA ZA200307102A patent/ZA200307102B/xx unknown
- 2003-09-15 IS IS6954A patent/IS6954A/is unknown
- 2003-10-09 NO NO20034538A patent/NO20034538L/no not_active Application Discontinuation
- 2003-11-24 BG BG108379A patent/BG108379A/bg unknown
-
2007
- 2007-09-12 US US11/853,949 patent/US20080004338A1/en not_active Abandoned
-
2008
- 2008-03-21 AT AT0017508U patent/AT10974U1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PL367480A1 (en) | 2005-02-21 |
| HUP0400054A2 (hu) | 2004-04-28 |
| US20040192765A1 (en) | 2004-09-30 |
| CZ20033267A3 (en) | 2004-06-16 |
| EA200301195A1 (ru) | 2004-04-29 |
| CN1509169A (zh) | 2004-06-30 |
| MXPA03008777A (es) | 2004-02-12 |
| KR20100012089A (ko) | 2010-02-05 |
| US20080004338A1 (en) | 2008-01-03 |
| US20040198811A1 (en) | 2004-10-07 |
| US20040198809A1 (en) | 2004-10-07 |
| BG108379A (bg) | 2004-11-30 |
| NO20034538D0 (no) | 2003-10-09 |
| YU85303A (sh) | 2006-05-25 |
| MEP5908A (xx) | 2010-02-10 |
| US20040198810A1 (en) | 2004-10-07 |
| US20040192766A1 (en) | 2004-09-30 |
| IL158031A0 (en) | 2004-03-28 |
| KR20040030609A (ko) | 2004-04-09 |
| AT10974U1 (de) | 2010-02-15 |
| US20040192764A1 (en) | 2004-09-30 |
| HUP0400054A3 (en) | 2007-03-28 |
| AR033308A1 (es) | 2003-12-10 |
| UA82828C2 (en) | 2008-05-26 |
| NO20034538L (no) | 2003-10-09 |
| HRP20030744A2 (en) | 2005-06-30 |
| ZA200307102B (en) | 2004-09-13 |
| BR0208283A (pt) | 2004-03-09 |
| WO2002087566A1 (en) | 2002-11-07 |
| CA2445843A1 (en) | 2002-11-07 |
| JP2004527551A (ja) | 2004-09-09 |
| EP1385503A1 (en) | 2004-02-04 |
| IS6954A (is) | 2003-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK14612003A3 (sk) | Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu | |
| HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| EA003142B1 (ru) | Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| KR20250069704A (ko) | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 | |
| RU2007103306A (ru) | Композиции на основе ризедроната и способы их применения | |
| AU2012276476B2 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| JP2007513095A5 (enExample) | ||
| Wilner et al. | Cannabinoids in the Treatment of Symptoms in Cancer and AIDS# 93: Megestrol Acetate for Cancer Anorexia/Cachexia# 100 | |
| EA011926B1 (ru) | Пероральный антидепрессивный состав, включающий ацетилсалициловую кислоту для ускорения начала действия | |
| HRP20100463A2 (hr) | Upotreba čistog enantiomernog citaloprama | |
| JP6878021B2 (ja) | トリプタンとアスコルビン酸を含有する医薬組成物 | |
| AU2008201217A1 (en) | The use of enantiomeric pure escitalopram | |
| AU2002254870A1 (en) | The use of enantiomeric pure escitalopram | |
| CN117750956A (zh) | 用于治疗抑郁状态的方法 | |
| HK40071665B (zh) | 在痴呆患者中治疗行为和精神症状 | |
| KR20210133495A (ko) | 옥수수불검화 정량 추출물 및 후박 추출물을 유효성분으로 포함하며 iLet(innovative Low excipient tablet) 기술을 이용한 정제사이즈 축소를 통해 복용 편의성이 향상된 치주질환 예방 또는 치료용 약학적 조성물 | |
| Van Moffaert et al. | A double-blind comparison o nefazodone and imipramine in the treatment of depressed patients | |
| Tran et al. | P. 2. c. 003 A placebo-controlled study of EB-1010, a novel triple re-uptake inhibitor, in patients with major depressive disorder | |
| MX2008004863A (es) | Métodos de tratamiento de desordenes del sistema nervioso central con una combinación de dosis baja de escitalopram y bupropion | |
| HK1067047A (en) | The use of enantiomeric pure escitalopram | |
| SI20854A (sl) | Farmacevtska zmes z učinkovino Brivudine z enkratnim dnevnim doziranjem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |